People taking GLP-1 drugs such as Ozempic and Wegovy typically lose about 15–20% of their body weight. Studies show these medications are usually considered long-term — often lifelong — because many people regain weight rapidly after stopping, sometimes returning to their original weight within two years. About 32% of people who begin GLP-1 therapy stop within a year, often because of cost or side effects.
A small study published in Obesity suggests some people may maintain weight loss while reducing injection frequency. The study followed 30 people who voluntarily tapered dosing: 24 reported a minimum of two weeks between injections (the longest interval was six weeks), while six used injections every 10 to 14 days. Participants kept the reduced schedule for an average of 36 weeks. Nearly all maintained the same BMI; four experienced slight regain, the largest being 8 pounds. Some even saw modest additional BMI reductions.
Researchers described structured de-escalation as a promising way to lower treatment burden without sacrificing efficacy. Bariatric surgeon Mir Ali, MD, noted similar clinical experiences: many patients successful on GLP-1s can use lower doses or less frequent injections to maintain weight loss. Endocrinologist Victoria Finn, MD, described a gradual decrease in dose and frequency to find the lowest effective regimen for preserving target weight, emphasizing that GLP-1s should be combined with regular physical activity and dietary adjustments.
Typical GLP-1 dosing for weight loss is once-weekly (some formulations daily). This small study indicates less frequent dosing might help people sustain results and make long-term use easier for some. However, experts caution tapering isn’t right for everyone. In the study, four people returned to their original dosing after regaining weight. Stopping GLP-1s abruptly isn’t recommended; reducing frequency or dose may be preferable to quitting entirely.
If validated in larger randomized trials, reduced-frequency strategies could address concerns about indefinite therapy, lower healthcare costs, ease supply constraints, and broaden access to GLP-1 medications. For now, clinicians and patients should treat obesity as a chronic condition and discuss individualized plans — including whether tapering is appropriate — under medical supervision.
